{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:50:55Z","timestamp":1761562255101,"version":"build-2065373602"},"reference-count":15,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1053\/j.ajkd.2017.05.010","type":"journal-article","created":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T09:15:35Z","timestamp":1498900535000},"page":"878-880","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Treatment of Gabapentin Toxicity With Peritoneal Dialysis: Assessment of Gabapentin Clearance"],"prefix":"10.1053","volume":"70","author":[{"given":"Hisham","family":"Ibrahim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zachary","family":"Oman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Schuelke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John C.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1053\/j.ajkd.2017.05.010_bib1","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1053\/j.ajkd.2009.10.050","article-title":"The management of diabetic neuropathy in CKD","volume":"55","author":"Pop-Busui","year":"2010","journal-title":"Am J Kidney Dis"},{"issue":"6 suppl 5","key":"10.1053\/j.ajkd.2017.05.010_bib2","first-page":"S17","article-title":"Clinical pharmacokinetics of gabapentin","volume":"44","author":"McLean","year":"1994","journal-title":"Neurology"},{"issue":"5","key":"10.1053\/j.ajkd.2017.05.010_bib3","first-page":"830","article-title":"Pharmacokinetics and metabolism of gabapentin in rat, dog and man","volume":"36","author":"Vollmer","year":"1986","journal-title":"Arzneimittel-Forschung"},{"issue":"suppl 9","key":"10.1053\/j.ajkd.2017.05.010_bib4","first-page":"S7","article-title":"The clinical pharmacokinetics of the new antiepileptic drugs","volume":"40","author":"Perucca","year":"1999","journal-title":"Epilepsia"},{"issue":"2","key":"10.1053\/j.ajkd.2017.05.010_bib5","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/clpt.1994.118","article-title":"Pharmacokinetics of gabapentin in subjects with various degrees of renal function","volume":"56","author":"Blum","year":"1994","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1053\/j.ajkd.2017.05.010_bib6","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.amjmed.2009.09.030","article-title":"Gabapentin toxicity in patients with chronic kidney disease: a preventable cause of morbidity","volume":"123","author":"Zand","year":"2010","journal-title":"Am J Med"},{"key":"10.1053\/j.ajkd.2017.05.010_bib7","doi-asserted-by":"crossref","DOI":"10.1136\/bcr.11.2008.1268","article-title":"Gabapentin toxicity: an important cause of altered consciousness in patients with uraemia","author":"Hung","year":"2009","journal-title":"BMJ Case Rep"},{"issue":"3","key":"10.1053\/j.ajkd.2017.05.010_bib8","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/00007691-200306000-00016","article-title":"Therapeutic drug monitoring of the newer antiepileptic drugs","volume":"25","author":"Johannessen","year":"2003","journal-title":"Ther Drug Monit"},{"issue":"6","key":"10.1053\/j.ajkd.2017.05.010_bib9","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-0031-1286287","article-title":"AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011","volume":"44","author":"Hiemke","year":"2011","journal-title":"Pharmacopsychiatry"},{"issue":"6","key":"10.1053\/j.ajkd.2017.05.010_bib10","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/j.1552-4604.1995.tb05020.x","article-title":"Disposition of gabapentin in anuric subjects on hemodialysis","volume":"35","author":"Wong","year":"1995","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"1","key":"10.1053\/j.ajkd.2017.05.010_bib11","doi-asserted-by":"crossref","first-page":"59","DOI":"10.4103\/0971-4065.83744","article-title":"Treatment of gabapentin-induced myoclonus with continuous renal replacement therapy","volume":"22","author":"Guddati","year":"2012","journal-title":"Indian J Nephrol"},{"key":"10.1053\/j.ajkd.2017.05.010_bib12","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ebcr.2013.12.002","article-title":"Myoclonus in renal failure: two cases of gabapentin toxicity","volume":"2","author":"Kaufman","year":"2014","journal-title":"Epilepsy Behav Case Rep"},{"issue":"2","key":"10.1053\/j.ajkd.2017.05.010_bib13","article-title":"[Rhabdomyolysis from gabapentin: a case report]","volume":"32","author":"Falconi","year":"2015","journal-title":"G\u00a0Ital Nefrol"},{"year":"2017","series-title":"Lexicomp Online","key":"10.1053\/j.ajkd.2017.05.010_bib14"},{"issue":"3","key":"10.1053\/j.ajkd.2017.05.010_bib15","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1136\/jcp.24.3.234","article-title":"Relationship between total body water and surface area in normal and obese subjects","volume":"24","author":"Hume","year":"1971","journal-title":"J\u00a0Clin Pathol"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638617307369?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638617307369?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T03:01:00Z","timestamp":1759460460000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638617307369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S0272638617307369"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2017.05.010","relation":{},"ISSN":["0272-6386"],"issn-type":[{"type":"print","value":"0272-6386"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of Gabapentin Toxicity With Peritoneal Dialysis: Assessment of Gabapentin Clearance","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2017.05.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}